N@N

Market Maker Surveillance Report. DELL, JNJ, HAL, ADXS, RPTP, ZNGA, Highest Net Buy Volume With Lowest Price Friction For Wedn

^{Published on 2012-06-13 18:00:41 - WOPRAI}
 

June 13, 2012 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 3532 companies with "abnormal" market making, 1765 companies with positive Friction Factors and 3757 companies with negative Friction Factors. Here is a list of the top companies with the highest net buy volume on Wednesday and lowest price Friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. DELL INC (NASDAQ:DELL), JOHNSON & JOHNSON (NYSE:JNJ), HALLIBURTON CO (NYSE:HAL), ADVAXIS INC (OTC:ADXS), RAPTOR PHARMACEUTICAL CORP (NASDAQ:RPTP), (NASDAQ:ZNGA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  DELL    $0.270    2.26%     22,706,083   53.88%    19,609,409   46.53%    3,096,674    114,692 
  JNJ     $1.220    1.93%     28,168,360   28.64%    23,955,434   24.36%    4,212,926    34,532  
  HAL     $0.090    0.32%     5,254,395    34.51%    3,636,799    23.89%    1,617,596    179,733 
  ADXS    $0.015    16.67%    3,743,570    66.71%    1,867,746    33.29%    1,875,824    1,250,549
  RPTP    $0.230    4.23%     2,713,720    86.52%    421,178      13.43%    2,292,542    99,676  
  ZNGA    $0.080    1.61%     11,594,975   54.21%    9,793,531    45.79%    1,801,444    225,181 

For example, the chart above shows DELL with a Net Buy Volume of 3,096,674 shares and a Friction Factor of 114,692 shares. That means that it takes 114,692 more shares of buying than selling to move DELL higher by one penny. This means the Market Makers are allowing the stock to move up higher as of Wednesday (lower friction). And with one of the highest Net Buy Volumes, the combination of low friction and high net buy volume is bullish.

DELL INC (NASDAQ:DELL) - Dell Inc. provides integrated technology solutions in the information technology (IT) industry worldwide. The company designs, develops, manufactures, markets, sells, and supports mobility products, including laptops, netbooks, tablets, and smartphones; desktops PCs; and servers and networking products. It also offers storage solutions comprising storage area networks, network-attached storage, direct-attached storage, disk and tape backup systems, and removable disk backup. In addition, the company provides third-party software products consisting of operating systems, business and office applications, anti-virus and related security software, and entertainment software; and peripherals, such as printers, televisions, notebook accessories, mice, keyboards, networking and wireless products, and digital cameras. In addition, it offers IT and business services, including transactional services, such as support, managed deployment, enterprise installation, and configuration services; outsourcing services comprising data center and systems management, network management, life cycle application development and management, and business process outsourcing services; and project-based services consisting of IT infrastructure, applications, business process, and business consulting services, as well as offers asset recovery, recycling, and applications maintenance services. Further, the company provides financial services, including originating, collecting, and servicing customer receivables related to the purchase of its products. Dell Inc. sells its products and services through its sales representatives, telephone-based sales, and online at dell.com, as well as through indirect sales channels. The company was founded in 1984 and is headquartered in Round Rock, Texas.

JOHNSON & JOHNSON (NYSE:JNJ) - Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment provides products used in baby care, skin care, oral care, wound care, and womens health care fields, as well as nutritional, over-the-counter pharmaceutical products, and wellness and prevention platforms under the names JOHNSONS, AVEENO, CLEAN & CLEAR, JOHNSONS Adult, NEUTROGENA, RoC, LUBRIDERM, Dabao, Vendome, LISTERINE, REACH, BAND-AID, PURELL, CAREFREE, STAYFREE, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID AC. The Pharmaceutical segment offers products in various therapeutic areas, such as anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, immunology, neurology, oncology, urology, and virology. Its products include REMICADE, a biologic approved for the treatment of immune mediated inflammatory diseases; PROCRIT, a biotechnology-derived product that stimulates red blood cell production; LEVAQUIN, which is used in the anti-infective field; RISPERDAL CONSTA, a injectable for the treatment of schizophrenia; CONCERTA, a product for the treatment of attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor; DURAGESIC/Fentanyl Transdermal, a treatment for chronic pain; VELCADE for the treatment of multiple myeloma; PREZISTA for treating HIV/AIDS patients; and INVEGA, a atypical antipsychotic. The Medical Devices and Diagnostics segment primarily offers circulatory disease management products; orthopaedic joint reconstruction, spinal care, and sports medicine products; surgical care, aesthetics, and womens health products; blood glucose monitoring and insulin delivery products; professional diagnostic products; and disposable contact lenses. The company was founded in 1886 and is based in New Brunswick, New Jersey.

HALLIBURTON CO (NYSE:HAL) - Halliburton Company provides various products and services to the energy industry for the exploration, development, and production of oil and natural gas worldwide. It operates in two segments, Completion and Production, and Drilling and Evaluation. The Completion and Production segment offers production enhancement services, completion tools and services, cementing services, and Boots & Coots. Its production enhancement services include stimulation and sand control services; completion tools and services comprise subsurface safety valves and flow control equipment, surface safety systems, packers and specialty completion equipment, intelligent completion systems, expandable liner hanger systems, sand control systems, well servicing tools, and reservoir performance services; cementing services consist of bonding the well and well casing, while isolating fluid zones and maximizing wellbore stability, and casing equipment; and Boots & Coots include well intervention services, pressure control, equipment rental tools and services, and pipeline and process services. The Drilling and Evaluation segment provides field and reservoir modeling, drilling, evaluation, and wellbore placement solutions that enable customers to model, measure, and optimize their well construction activities. Its services comprise fluid services, drilling services, drill bits, wireline and perforating services, testing and subsea services, software and asset solutions, and integrated project management and consulting services. The company serves independent, integrated, and national oil companies. Halliburton Company was founded in 1919 and is headquartered in Houston, Texas.

ADVAXIS INC (OTC:ADXS) - Advaxis, Inc., a development stage biotechnology company, engages in the research and development of cancer-fighting techniques primarily in the United States. The company develops therapeutic cancer vaccines targeting cervical, head and neck, breast, prostate, and other cancers. Its products in development stage include ADXS11-001, a Phase I/II trial product for cervical intraepithelial neoplasia, cervical cancer, and head and neck cancer; ADXS31-142, a Phase I trial product for prostate cancer; and ADXS31-164, a Phase I trial product for breast cancer. The company has strategic collaboration agreement with Cobra Biomanufacturing PLC to manufacture cervical cancer vaccine. Advaxis, Inc. was founded in 2002 and is based in North Brunswick, New Jersey.

RAPTOR PHARMACEUTICAL CORP (NASDAQ:RPTP) - Raptor Pharmaceuticals Corp. operates as a development stage biotechnology company in the United States. The company engages in the discovery, research, and preclinical development of drug candidates and drug-targeting platforms for the treatment of various brain disorders and neurodegenerative diseases, genetic disorders, and cancer through the proprietary use of receptor-associated proteins and mesoderm development proteins. Its clinical-stage products include DR Cysteamine, which is in Phase IIb clinical trail for the treatment of nephropathic cystinosis or cystinosis; and in Phase IIa clinical trail for the treatment of non-alcoholic steatohepatitis. The company also develops Convivia, a Phase IIa clinical trail product for the treatment of aldehyde dehydrogenase or ALDH2 deficiency; DR Cysteamine, which is in Phase II clinical trail for the treatment of Huntingtons Disease; and Tezampanel and NGX 426 that is in Phase II clinical trail for the treatment of migraine, acute pain, and chronic pain. In addition, its preclinical development products comprise HepTide for the treatment of Hepatocellular Carcinoma and Hepatitis C; WntTide for the treatment of breast cancer; and NeuroTrans for the treatment of neurodegenerative diseases. The company has collaboration agreements with the University of California, San Diego for a clinical study of DR Cysteamine in juvenile patients with Non-Alcoholic Steatohepatitis and to study DR Cysteamine in patients with cystinosis. Raptor Pharmaceuticals Corp was founded in 2005 and is based in Novato, California.

(NASDAQ:ZNGA) -

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net